

Universal Biosensors Inc  
ARBN 121 559 993

1 Corporate Avenue  
Rowville VIC 3178  
Australia

Telephone +61 3 9213 9000  
Facsimile +61 3 9213 9099  
Email [info@universalbiosensors.com](mailto:info@universalbiosensors.com)  
[www.universalbiosensors.com](http://www.universalbiosensors.com)



**Universal Biosensors**

13 March 2015

## **Point of Care Coagulation Testing – Product Development Update**

The Xprecia Stride™ Coagulation Analyzer was the first point-of-care coagulation testing system developed with Siemens, and was launched in December 2014. As previously advised, further point-of-care coagulation tests are also in development in collaboration with Siemens.

Siemens and UBI have now agreed on additional payments to be made by Siemens to UBI to incorporate certain additional features that are expected to have high commercial value for the use of these tests. Siemens and UBI are now targeting the second half of 2016 for regulatory approval and commercial launch of these additional tests by Siemens.

UBI continues to advance the development of its own PT-INR test for decentralised settings and continues to target product launch in late 2015. Reliability and clinical testing are underway and preparations are now being made for final design verification and regulatory trials.

Paul Wright, CEO of Universal Biosensors said: *"Following the successful development of the Xprecia Stride™ Coagulation Analyzer for Siemens, it's exciting to have several new point-of-care coagulation testing products coming down the pipeline that will deliver new revenue streams and further accelerate growth for UBI."*

The worldwide point-of-care coagulation testing market was estimated at ~\$1.0 billion in 2014 and is forecast to grow by ~9% per annum to ~\$1.4 billion by 2018. The coagulation testing market is dominated by PT-INR testing, which represents over 65% of this market today.

## **Ends**

Enquiries:  
Mr Paul Wright: 03 9213 9000

## **About Universal Biosensors**

For additional information in relation to Universal Biosensors, refer to <http://www.universalbiosensors.com>.

Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.

## **Forward-Looking Statements**

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the Exchange Act. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies regarding the proposed offering. All forward-looking statements

Universal Biosensors Inc  
ARBN 121 559 993

1 Corporate Avenue  
Rowville VIC 3178  
Australia

Telephone +61 3 9213 9000  
Facsimile +61 3 9213 9099  
Email [info@universalbiosensors.com](mailto:info@universalbiosensors.com)  
[www.universalbiosensors.com](http://www.universalbiosensors.com)



**Universal Biosensors**

included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposed offering will occur, and the terms of any such offering are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.